FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA
Approval of YARTEMLEA was based on results from a single-arm, open-label study in adults with TA-TMA (the TA-TMA…
PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
Moitreyee Chatterjee-Kishore, PhD, MBA, Head of Oncology Development, Astellas“Building on the recent U.S. approval for cisplatin-ineligible patients living…